Where the stock stands
Aurobindo Pharma Ltd., a Healthcare-sector name, was last marked at ₹1,613.4 on 5 August 2026, a gain of 1.73% over the previous close of ₹1,585.9. The Nifty moved 0.04% on the day, so this was a stock-specific move. The shares sit 1.43% under the 52-week high of ₹1,636.8 and 58.78% above the 52-week low of ₹1,016.1 — the upper end of their own one-year range.
The return profile is front-loaded into the longer windows: about 1.4% over the past week and 1.9% over the past month, roughly 8.4% over three months, and close to 39.3% over one year. On the reported valuation figures the company carries a market capitalisation of ₹92,831 crore, a price-to-earnings ratio of 26.73, a price-to-book of 2.47, earnings per share of 60.36, return on equity of 9.9% and a dividend yield of 0.25%.
What the smart-money flow shows
The clearest positioning signal is in the futures market, where the screen classifies the stock as a long buildup — fresh futures positions opened while the price advanced, rather than old short positions being closed out. Open interest expanded 5.61% alongside a 2.5% price change in the futures leg. That is money being committed on the long side rather than unwound from the short one, though it is one snapshot: a single day of open-interest change says nothing about how long those positions stay.
Beyond that, the evidence is thin on the flows retail investors most often look for. It carries no named bulk or block deals, no record of a foreign or domestic institutional buying or selling streak, and no insider or promoter filings. Their absence is not proof that nothing happened, only that this dataset captures none — so it supports no conclusion about institutional conviction.
What the data does carry is a run of exchange intimations. On 5 August the company told the exchange of a proposed merger involving two of its wholly owned stepdown subsidiaries and another wholly owned subsidiary. Across 23, 24 and 25 July it filed, repeatedly, on taking majority ownership of A1 Biochem Labs (India) Private Limited along with A1 Biochem Labs LLC in the United States. The screen tags these as bullish in bias, which classifies the event type rather than any measured market outcome.
The technical picture
Price is above both the 50-day and the 200-day moving average, and the data records neither a golden cross nor a death cross — the two averages have not crossed recently in either direction. The 14-period RSI, a momentum oscillator running from 0 to 100, reads 61.4, above the midpoint without being at an extreme. Relative volume came in at 1.5, meaning turnover ran about one and a half times the stock's typical level, so the move came on heavier-than-usual participation.
Catalysts and what to watch
Several dated items cluster on the same day. According to a report in the news feed, the shares gained on a USFDA approval for Tofacitinib tablets. A Reuters headline reports quarterly profit rising on anti-retroviral drug demand, and an NDTV Profit headline puts that at a 25% jump in profit with revenue at Rs 9,150 crore and improving margins. The results date in the data is 5 August 2026, against an EPS estimate of ₹17 per share. Earlier, on 23 July, the company intimated receipt of an ANVISA approval for the biosimilars manufacturing facility of CuraTeQ Biologics Private Limited, a wholly owned subsidiary per that filing.
Two wider items sit in the feed without a company-specific link: a Goodreturns roundup of upcoming corporate actions that lists the stock, and a Wall Street Journal headline from two weeks earlier reporting generic-drug makers falling after a tariff plan. Taken together, the data shows a stock trading near its 52-week high with a long futures buildup and a dense cluster of approval, merger and results headlines on one date. It does not establish which of those the price was responding to, and it offers no institutional or insider flow at all to corroborate the futures signal.